Clinical trials: Circulating Tumor Cell;
Non Small Cell Lung Cancer Metastatic, Non Small Cell Lung Cancer Recurrent
Cancer Panel From Blood of Lung Cancer Patients
Molecular profiling of lung cancers using circulating tumor DNA (ctDNA) in the blood of patients is rapidly becoming established as a useful source of information to aid clinical decision-making.
- Trial name
- CAPABLE (NCT03235765)
- Testing
- MACROGEN Pan Cancer Panel (Tier 2)
- Where
- South Korea
- Volunteers
- 200 people
- Sponsor
- Seoul National University Hospital
Lymphoma, Lymphoma, B-Cell
ctDNA-guided Therapy Optimization in Newly Diagnosed DLBCL
The purpose of this study is to 1) determine whether it is feasible to measure circulating tumor DNA (ctDNA) in real-time during standard treatment for newly diagnosed diffuse large B-cell lymphoma (DLBCL), and 2) evaluate the…
- Conditions
- Lymphoma, Lymphoma, B-Cell, Diffuse Large B Cell Lymphoma, Diffuse Large B-Cell Lymphoma, Not Otherwise Specified
- Trial name
- NCT06693830
- Testing
- Phased Variant Enrichment and Detection Sequencing (PhasED-seq), Standard of Care Treatment, De-escalated Treatment
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- Hua-Jay J Cherng, MD
Breast Cancer, Prostate Cancer
Enumeration and Functional Analysis of Circulating Tumor Cells for Homologous Recombination: a Prospective Single-center Study on Advanced/Metastatic Solid Tumors
The goal of this clinical trial is to is to evaluate whether a correlation exists between functional HR status/CTC enumeration in expanded CTCs measured before treatment initiation, and Progression Free Survival (PFS) under PARPi…
- Conditions
- Breast Cancer, Prostate Cancer, Pancreatic Cancer, Ovarian Cancer
- Trial name
- E-FACTOR (NCT07555600)
- Testing
- blood sampling, Tumor sampling
- Volunteers
- 300 people
- Sponsor
- Centre Leon Berard
Carcinoma, Non-Small-Cell Lung, Bronchial Neoplasms
Dynamic Changes of Circulating Tumor DNA in Late Stage NSCLC Patients
A multi-centre observational, non-interventional study is to dynamically monitor the changes of circulating tumor DNA (ctDNA) in late stage NSCLC patients under Gefitinib treatment.
- Conditions
- Carcinoma, Non-Small-Cell Lung, Bronchial Neoplasms, Carcinoma, Bronchogenic, Lung Diseases
- Trial name
- NCT02804100
- Where
- China
- Volunteers
- 200 people
- Sponsor
- Wenzhou Medical University
Circulating Tumor Cell, Gastrointestinal Cancer
EUS Guided HVA and PVA for Circulating Tumor DNA in Patients
The discovery of cell-free circulating tumor DNA (crDNA) in blood and the maturation of technologies for ctDNA analysis have presented an attractive opportunity for minimally invasive "liquid biopsy" genomic diagnostics.
- Trial name
- NCT04782557
- Testing
- EUS-guided portal vein and hepatic vein aspiration
- Where
- Hong Kong
- Volunteers
- 60 people
- Sponsor
- Chinese University of Hong Kong
Diffuse Large B-cell Lymphoma
Assessing a ctDNA and PET-oriented Therapy in Patients With DLBCL A Multicenter, Open-label, Phase II Trial.
Within this exploratory multicohort phase II trial, SAKK aims to evaluate a PET/CT and ctDNA oriented therapy in DLBCL in order to test the following working hypothesis.
- Trial name
- NCT04604067
- Testing
- Acalabrutinib
- Where
- 19 sites in Italy, Switzerland
- Volunteers
- 260 people
- Sponsor
- Swiss Cancer Institute
Glioblastoma, Molecular Disease
Evaluation of Circulating Tumor DNA as a Theranostic Marker in the Management of Glioblastomas.
Glioblastomas (GBM) are rare tumors of poor prognosis and their treatment is based on surgery followed by radiochemotherapy. Clinical and imaging evaluation is not always straightforward: the more or less complete surgery, the…
- Trial name
- Bi-GLAM (NCT03115138)
- Testing
- Correlation between molecular anomalies of the primary tumor and circulating tumor DNA
- Where
- France
- Volunteers
- 19 people
- Sponsor
- Centre Hospitalier Universitaire, Amiens
Lung Cancer, Colorectal Cancer
ProSight: A Multi-centre Interventional Study Evaluating MCED in Asymptomatic Population
This is a prospective, multi-centre interventional study evaluating the feasibility of blood-based multi-cancer early detection test in asymptomatic screening cohort.
- Conditions
- Lung Cancer, Colorectal Cancer, Liver Cancer, Grastic Cancer
- Trial name
- NCT06790355
- Testing
- multi-cancer early detection
- Where
- 4 sites in China
- Volunteers
- 2,527 people, healthy volunteers welcome
- Sponsor
- Shanghai Weihe Medical Laboratory Co., Ltd.
Non-small Cell Lung Cancer, ALK-Positive Lung Cancer
Plasma Molecular Profiling in ALK Inhibitor Resistant NSCLC
The investigators plan to understand a comprehensive molecular profiling via the plasma, with the primary aim of using this form on analysis to guide subsequent treatment selection.
- Trial name
- NCT04087473
- Where
- 5 sites in Hong Kong, Malaysia and 2 more
- Volunteers
- 50 people
- Sponsor
- National Cancer Centre, Singapore
Lymphoma
A Study to Evaluate the Safety and Efficacy of Glofitamab in Combination With Rituximab (R) Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (CHOP) in Circulating Tumor (ct)DNA High-Risk Patients With Untreated Diffuse Large B-Cell Lymphoma
This Phase II, open-label, multicenter study will evaluate the safety, efficacy, and pharmacokinetics of glofitamab in combination with rituximab in combination with cyclophosphamide, doxorubicin, vincristine, and prednisone…
- Trial name
- NCT04980222
- Testing
- Glofitamab, Tocilizumab, Doxorubicin
- Where
- 20 sites in United States, Denmark and 4 more
- Volunteers
- 46 people
- Sponsor
- Hoffmann-La Roche
Non Small Cell Lung Cancer
A2R and Ectonucleotidases Expression in Lung Cancer Circulating Tumor Cells
Early non-small cell lung cancer (NSCLC), treated by surgery or radiotherapy in the case of inoperability, relapses in almost 50% of cases.
- Trial name
- LUNGadenosine (NCT05648188)
- Testing
- Sample
- Where
- France
- Sponsor
- Centre Hospitalier Universitaire de Nice
Bladder Cancer, Circulating Tumor Cells
Detection and Clinical Significance of Circulating Cancer Cells in Patient Undergoing Radical Cystectomy
Very few factors may be identified as prognostic for patients with bladder cancer undergoing radical cystectomy. Recently, detection of circulating tumor cells has shown to be very promising in anticipating both the likelyhood of…
- Trial name
- CirCanCell (NCT02345473)
- Testing
- Detection of circulating tumor cells in blood samples
- Where
- Italy
- Volunteers
- 59 people, healthy volunteers welcome
- Sponsor
- Azienda Ospedaliero-Universitaria Consorziale Policlinico di Bari
NSCLC, Stage IV
Early Response Evaluation in NSCLC Patients Treated With Immunotherapy
A pilot study with biomarker exploration.50 patients with stage IV non-small cell lung cancer (NSCLC) that are eligible for treatment with nivolumab.
- Trial name
- NCT04082988
- Testing
- 18F-FDG PET-CT
- Where
- 2 sites in Netherlands
- Volunteers
- 9 people
- Sponsor
- The Netherlands Cancer Institute
Melanoma
ctDNA for Early Detection of Recurrence in Melanoma
This study examines circulating tumor DNA (ctDNA) as a biomarker for early detection of recurrence in high-risk patients, following treatment of primary melanoma.
- Trial name
- NCT06246227
- Where
- Denmark
- Volunteers
- 467 people
- Sponsor
- Herlev and Gentofte Hospital
HPV-Associated Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
Risk-adapted Therapy in HPV+ Oropharyngeal Cancer Using Circulating Tumor (ct)HPV DNA Profile - The ReACT Study
This research is being conducted to understand if treatment can be tailored for participants with HPV-related oropharynx cancers using both clinical features (stage of the tumor, smoking status) combined with an investigational…
- Conditions
- HPV-Associated Oropharyngeal Squamous Cell Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma, HPV-Mediated (P16-Positive) Oropharyngeal Carcinoma by AJCC V8 Stage, HPV-Related Squamous Cell Carcinoma
- Trial name
- NCT04900623
- Testing
- NavDx HPV ctDNA Testing, Radiotherapy, Chemotherapy drug
- Where
- 2 sites in United States
- Volunteers
- 145 people
- Sponsor
- Jonathan Schoenfeld, MD, MPH
Oropharyngeal Cancer, HPV-Related Carcinoma
A Study Using Human Papillomavirus (HPV) DNA Testing to Detect HPV-Related Oropharyngeal Cancer (OPC)
The researchers think that a blood test (NavDx®) may be able to identify cancer early by looking for circulating DNA from Human Papillomavirus/HPV. Circulating DNA are small pieces of genes that are released into the bloodstream.
- Conditions
- Oropharyngeal Cancer, HPV-Related Carcinoma, HPV Positive Oropharyngeal Squamous Cell Carcinoma
- Trial name
- NCT05814549
- Testing
- NavDx
- Where
- 7 sites in United States
- Volunteers
- 9 people, healthy volunteers welcome
- Sponsor
- Memorial Sloan Kettering Cancer Center
Carcinoma, Non-small-cell Lung Cancer
Urinary Circulating Tumor DNA Detection in Non-small Cell Lung Cancer: a Prospective Study
This study will evaluate the feasibility and effectiveness of urinary ctDNA detection and dynamic monitoring during treatment of NSCLC patients prospectively,by collecting and detecting tumor tissues, peripheral blood samples and…
- Conditions
- Carcinoma, Non-small-cell Lung Cancer, Lung Neoplasms
- Trial name
- NCT02907606
- Where
- China
- Volunteers
- 45 people
- Sponsor
- Peking University People's Hospital
Peripheral T-cell Lymphoma, NK/T-Cell Lymphoma
Circulating Tumor DNA in Peripheral T-cell Lymphomas
The aim of this study is to evaluate the feasibility of circulating tumor DNA (ctDNA) measurement in blood plasma for the applicability in prognostication, treatment evaluation and measurable residual disease (MRD) surveillance…
- Trial name
- CIRCULATE (NCT06362148)
- Testing
- Tumor- and plasma-informed, next-generation sequencing (NGS)-based patient-specific droplet digital (dd)PCR assay, 18F-fludeoxyglucose positron emission tomography/computed tomography (FDG-PET/CT)
- Where
- Denmark
- Volunteers
- 50 people
- Sponsor
- University of Aarhus
Prostate Cancer, Metastatic Cancer
CTC, Free DNA, Stem Cells and EMT-related Antigens as Biomarkers of Activity of Cabazitaxel in CRPC.
Identification of biomarkers (Circulating Tumor Cells (CTC), free DNA, Stem Cells and EMT-related antigens) that may be predictive of outcome of activity of cabazitaxel treatment in castration-resistant prostate cancer.
- Conditions
- Prostate Cancer, Metastatic Cancer, Castration-resistant Prostate Cancer, Circulating Tumor Cells
- Trial name
- IRSTB030 (NCT03381326)
- Testing
- blood and FFPE sample collection
- Where
- 9 sites in Italy
- Volunteers
- 104 people
- Sponsor
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Stage II Bladder Urothelial Carcinoma
Circulating Tumor Cells in Operative Blood in Patients With Bladder Cancer
This pilot clinical trial studies the impact of radical cystectomy (surgery) on the expulsion (release) of circulating tumor cells into the blood stream in patients with bladder cancer.
- Trial name
- NCT02514408
- Testing
- Catheter Management, Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis
- Sponsor
- University of Southern California